MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$1,070K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Net income/(loss)
    • Issuance of shares, options exer...
    • Stock-based compensation
    • Others
Negative Cash Flow Breakdown
    • Accounts receivable
    • Cash paid for taxes on restricte...
    • Accounts payable
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net income/(loss)
1,973
5,155
-637
-4,317
Inventory reserve
-
-
-517
-
Allowance for credit losses
-287
-120
-1,155
1,222
Amortization of debt discount
-
-
12
26
Loss on securities
-
-
0
2
Amortization of norgine asset
25
-51
26
51
Stock-based compensation
1,774
-3,521
2,219
2,292
Accounts receivable
4,217
-13,494
3,440
5,542
Prepaid expenses
174
1,404
-3,340
1,659
Other assets
-
-
-520
435
Inventory
518
-1,126
276
1,141
Other current assets
-646
891
-
-
Other non-current assets
-1,664
1,460
-
-
Accounts payable
-765
-979
-75
2,700
Accrued liabilities
639
-2,851
1,476
-1,203
Contract liability
-710
-
-
-
Net cash provided by/(used in) operating activities
50
8,890
1,493
-8,004
Issuance of shares, options exercise
1,961
-662
1,799
186
Cash paid for taxes on restricted share release
941
150
50
111
Net cash provided by financing activities
1,020
-812
1,749
75
Increase/(decrease) in cash and cash equivalents
1,070
8,078
3,242
-7,929
Cash and cash equivalents - beginning of year
21,947
21,947
26,634
-
Cash and cash equivalents - end of year
41,249
40,179
21,947
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Issuance of shares,options exercise$1,961K (954.30%↑ Y/Y)Net income/(loss)$1,973K (145.70%↑ Y/Y)Stock-based compensation$1,774K (-22.60%↓ Y/Y)Other non-currentassets-$1,664K Other current assets-$646K Accrued liabilities$639K (153.12%↑ Y/Y)Amortization of norgine asset$25K (-50.98%↓ Y/Y)Net cash provided byfinancing activities$1,020K (1260.00%↑ Y/Y)Net cash providedby/(used in) operating...$50K (100.62%↑ Y/Y)Canceled cashflow$941K Canceled cashflow$6,671K Increase/(decrease) in cash and cashequivalents$1,070K (113.49%↑ Y/Y)Cash paid for taxes onrestricted share release$941K (747.75%↑ Y/Y)Accounts receivable$4,217K (-23.91%↓ Y/Y)Accounts payable-$765K (-128.33%↓ Y/Y)Contract liability-$710K Inventory$518K (-54.60%↓ Y/Y)Allowance for creditlosses-$287K (-123.49%↓ Y/Y)Prepaid expenses$174K (-89.51%↓ Y/Y)

FENNEC PHARMACEUTICALS INC. (FENC)

FENNEC PHARMACEUTICALS INC. (FENC)